B-intervention	0	10	Overweight
I-intervention	10	11	,
I-intervention	12	19	Obesity
O	19	20	,
O	21	24	and
O	25	39	Postmenopausal
O	40	48	Invasive
O	49	55	Breast
O	56	62	Cancer
O	63	67	Risk
O	67	68	:
O	69	70	A
O	71	80	Secondary
O	81	89	Analysis
O	90	92	of
O	93	96	the
O	97	102	Women
O	102	103	'
O	103	104	s
O	105	111	Health
O	112	122	Initiative
O	123	133	Randomized
O	134	142	Clinical
O	143	149	Trials
O	149	150	.

O	151	155	More
O	156	160	than
O	161	164	two
O	164	165	-
O	165	171	thirds
O	172	174	of
O	175	177	US
O	178	183	women
O	184	187	are
O	188	198	overweight
O	199	201	or
O	202	207	obese
O	207	208	,
O	209	216	placing
O	217	221	them
O	222	224	at
O	225	234	increased
O	235	239	risk
O	240	243	for
O	244	258	postmenopausal
O	259	265	breast
O	266	272	cancer
O	272	273	.

O	274	276	To
O	277	288	investigate
O	289	291	in
O	292	296	this
O	297	306	secondary
O	307	315	analysis
O	316	319	the
O	320	332	associations
O	333	335	of
O	336	346	overweight
O	347	350	and
O	351	358	obesity
O	359	363	with
O	364	368	risk
O	369	371	of
O	372	386	postmenopausal
O	387	395	invasive
O	396	402	breast
O	403	409	cancer
O	410	415	after
O	416	424	extended
O	425	431	follow
O	431	432	-
O	432	434	up
O	435	437	in
O	438	441	the
O	442	447	Women
O	447	448	'
O	448	449	s
O	450	456	Health
O	457	467	Initiative
O	468	469	(
O	469	472	WHI
O	472	473	)
O	474	482	clinical
O	483	489	trials
O	489	490	.

O	491	494	The
O	495	498	WHI
O	499	507	clinical
O	508	513	trial
O	514	522	protocol
O	523	535	incorporated
O	536	544	measured
O	545	551	height
O	552	555	and
O	556	562	weight
O	562	563	,
O	564	572	baseline
O	573	576	and
O	577	583	annual
O	584	586	or
O	587	595	biennial
O	596	607	mammography
O	607	608	,
O	609	612	and
O	613	624	adjudicated
O	625	631	breast
O	632	638	cancer
O	639	642	end
O	643	649	points
O	650	652	in
B-total-participants	653	655	67
I-total-participants	656	659	142
B-eligibility	660	674	postmenopausal
I-eligibility	675	680	women
O	681	685	ages
B-age	686	688	50
I-age	689	691	to
I-age	692	694	79
I-age	695	700	years
O	701	703	at
O	704	706	40
B-location	707	709	US
O	710	718	clinical
O	719	726	centers
O	726	727	.

O	728	731	The
O	732	737	women
O	738	742	were
O	743	751	enrolled
O	752	756	from
O	757	761	1993
O	762	764	to
O	765	769	1998
O	770	774	with
O	775	776	a
O	777	783	median
O	784	786	of
O	787	789	13
O	790	795	years
O	796	798	of
O	799	805	follow
O	805	806	-
O	806	808	up
O	809	816	through
O	817	821	2010
O	821	822	;
O	823	827	3388
B-outcome	828	836	invasive
I-outcome	837	843	breast
I-outcome	844	851	cancers
O	852	856	were
O	857	865	observed
O	865	866	.

O	867	873	Height
O	874	877	and
O	878	884	weight
O	885	889	were
O	890	898	measured
O	899	901	at
O	902	910	baseline
O	910	911	,
O	912	915	and
O	916	922	weight
O	923	926	was
O	927	935	measured
O	936	944	annually
O	945	955	thereafter
O	955	956	.

O	957	961	Data
O	962	966	were
O	967	976	collected
O	977	979	on
O	980	991	demographic
O	992	1007	characteristics
O	1007	1008	,
O	1009	1017	personal
O	1018	1021	and
O	1022	1028	family
O	1029	1036	medical
O	1037	1044	history
O	1044	1045	,
O	1046	1049	and
O	1050	1058	personal
O	1059	1065	habits
O	1066	1067	(
O	1067	1074	smoking
O	1074	1075	,
O	1076	1084	physical
O	1085	1093	activity
O	1093	1094	)
O	1094	1095	.

O	1096	1101	Women
O	1102	1111	underwent
O	1112	1118	annual
O	1119	1121	or
O	1122	1130	biennial
O	1131	1141	mammograms
O	1141	1142	.

O	1143	1149	Breast
O	1150	1157	cancers
O	1158	1162	were
O	1163	1171	verified
O	1172	1174	by
O	1175	1182	medical
O	1183	1190	records
O	1191	1199	reviewed
O	1200	1202	by
O	1203	1212	physician
O	1213	1225	adjudicators
O	1225	1226	.

O	1227	1232	Women
O	1233	1236	who
O	1237	1241	were
O	1242	1252	overweight
O	1253	1256	and
O	1257	1262	obese
O	1263	1266	had
O	1267	1269	an
B-outcome	1270	1279	increased
I-outcome	1280	1288	invasive
I-outcome	1289	1295	breast
I-outcome	1296	1302	cancer
I-outcome	1303	1307	risk
O	1308	1310	vs
O	1311	1316	women
O	1317	1319	of
O	1320	1326	normal
O	1327	1333	weight
O	1333	1334	.

O	1335	1339	Risk
O	1340	1343	was
O	1344	1352	greatest
O	1353	1356	for
O	1357	1364	obesity
O	1365	1370	grade
O	1371	1372	2
O	1373	1377	plus
O	1378	1379	3
O	1380	1381	(
O	1381	1385	body
O	1386	1390	mass
O	1391	1396	index
O	1397	1398	[
O	1398	1401	BMI
O	1401	1402	]
O	1402	1403	,
O	1404	1414	calculated
O	1415	1417	as
O	1418	1424	weight
O	1425	1427	in
O	1428	1437	kilograms
O	1438	1445	divided
O	1446	1448	by
O	1449	1455	height
O	1456	1458	in
O	1459	1465	meters
O	1466	1473	squared
O	1473	1474	,
O	1475	1476	>
O	1476	1478	35
O	1478	1479	.
O	1479	1480	0
O	1480	1481	)
O	1482	1483	(
O	1483	1489	hazard
O	1490	1495	ratio
O	1496	1497	[
O	1497	1499	HR
O	1499	1500	]
O	1501	1504	for
O	1505	1513	invasive
O	1514	1520	breast
O	1521	1527	cancer
O	1527	1528	,
O	1529	1530	1
O	1530	1531	.
O	1531	1533	58
O	1533	1534	;
O	1535	1537	95
O	1537	1538	%
O	1539	1541	CI
O	1541	1542	,
O	1543	1544	1
O	1544	1545	.
O	1545	1547	40
O	1547	1548	-
O	1548	1549	1
O	1549	1550	.
O	1550	1552	79
O	1552	1553	)
O	1553	1554	.

O	1555	1556	A
O	1557	1560	BMI
O	1561	1563	of
O	1564	1566	35
O	1566	1567	.
O	1567	1568	0
O	1569	1571	or
O	1572	1578	higher
O	1579	1582	was
O	1583	1591	strongly
O	1592	1602	associated
O	1603	1607	with
B-outcome	1608	1612	risk
I-outcome	1613	1616	for
I-outcome	1617	1625	estrogen
I-outcome	1626	1634	receptor
I-outcome	1634	1635	-
I-outcome	1635	1643	positive
I-outcome	1644	1647	and
I-outcome	1648	1660	progesterone
I-outcome	1661	1669	receptor
I-outcome	1669	1670	-
I-outcome	1670	1678	positive
I-outcome	1679	1685	breast
I-outcome	1686	1693	cancers
O	1694	1695	(
O	1695	1697	HR
O	1697	1698	,
O	1699	1700	1
O	1700	1701	.
O	1701	1703	86
O	1703	1704	;
O	1705	1707	95
O	1707	1708	%
O	1709	1711	CI
O	1711	1712	,
O	1713	1714	1
O	1714	1715	.
O	1715	1717	60
O	1717	1718	-
O	1718	1719	2
O	1719	1720	.
O	1720	1722	17
O	1722	1723	)
O	1724	1727	but
O	1728	1731	was
O	1732	1735	not
O	1736	1746	associated
O	1747	1751	with
O	1752	1760	estrogen
O	1761	1769	receptor
O	1769	1770	-
O	1770	1778	negative
O	1779	1786	cancers
O	1786	1787	.

O	1788	1795	Obesity
O	1796	1801	grade
O	1802	1803	2
O	1804	1808	plus
O	1809	1810	3
O	1811	1814	was
O	1815	1819	also
O	1820	1830	associated
O	1831	1835	with
B-outcome	1836	1844	advanced
I-outcome	1845	1852	disease
I-outcome	1852	1853	,
I-outcome	1854	1863	including
I-outcome	1864	1870	larger
I-outcome	1871	1876	tumor
I-outcome	1877	1881	size
O	1882	1883	(
O	1883	1885	HR
O	1885	1886	,
O	1887	1888	2
O	1888	1889	.
O	1889	1891	12
O	1891	1892	;
O	1893	1895	95
O	1895	1896	%
O	1897	1899	CI
O	1899	1900	,
O	1901	1902	1
O	1902	1903	.
O	1903	1905	67
O	1905	1906	-
O	1906	1907	2
O	1907	1908	.
O	1908	1910	69
O	1910	1911	;
O	1912	1913	P
O	1914	1915	=
O	1916	1917	.
O	1917	1919	02
O	1919	1920	)
O	1920	1921	,
B-outcome	1922	1930	positive
I-outcome	1931	1936	lymph
I-outcome	1937	1942	nodes
O	1943	1944	(
O	1944	1946	HR
O	1946	1947	,
O	1948	1949	1
O	1949	1950	.
O	1950	1952	89
O	1952	1953	;
O	1954	1956	95
O	1956	1957	%
O	1958	1960	CI
O	1960	1961	,
O	1962	1963	1
O	1963	1964	.
O	1964	1966	46
O	1966	1967	-
O	1967	1968	2
O	1968	1969	.
O	1969	1971	45
O	1971	1972	;
O	1973	1974	P
O	1975	1976	=
O	1977	1978	.
O	1978	1980	06
O	1980	1981	)
O	1981	1982	,
B-outcome	1983	1991	regional
I-outcome	1992	1995	and
I-outcome	1995	1996	/
I-outcome	1996	1998	or
I-outcome	1999	2006	distant
I-outcome	2007	2012	stage
O	2013	2014	(
O	2014	2016	HR
O	2016	2017	,
O	2018	2019	1
O	2019	2020	.
O	2020	2022	94
O	2022	2023	;
O	2024	2026	95
O	2026	2027	%
O	2028	2030	CI
O	2030	2031	,
O	2032	2033	1
O	2033	2034	.
O	2034	2036	52
O	2036	2037	-
O	2037	2038	2
O	2038	2039	.
O	2039	2041	47
O	2041	2042	;
O	2043	2044	P
O	2045	2046	=
O	2047	2048	.
O	2048	2050	05
O	2050	2051	)
O	2051	2052	,
O	2053	2056	and
B-outcome	2057	2063	deaths
I-outcome	2064	2069	after
I-outcome	2070	2076	breast
I-outcome	2077	2083	cancer
O	2084	2085	(
O	2085	2087	HR
O	2087	2088	,
O	2089	2090	2
O	2090	2091	.
O	2091	2093	11
O	2093	2094	;
O	2095	2097	95
O	2097	2098	%
O	2099	2101	CI
O	2101	2102	,
O	2103	2104	1
O	2104	2105	.
O	2105	2107	57
O	2107	2108	-
O	2108	2109	2
O	2109	2110	.
O	2110	2112	84
O	2112	2113	;
O	2114	2115	P
O	2116	2117	<
O	2118	2119	.
O	2119	2122	001
O	2122	2123	)
O	2123	2124	.

O	2125	2130	Women
O	2131	2135	with
O	2136	2137	a
O	2138	2146	baseline
O	2147	2150	BMI
O	2151	2153	of
O	2154	2158	less
O	2159	2163	than
O	2164	2166	25
O	2166	2167	.
O	2167	2168	0
O	2169	2172	who
O	2173	2179	gained
O	2180	2184	more
O	2185	2189	than
O	2190	2191	5
O	2191	2192	%
O	2193	2195	of
O	2196	2200	body
O	2201	2207	weight
O	2208	2212	over
O	2213	2216	the
O	2217	2223	follow
O	2223	2224	-
O	2224	2226	up
O	2227	2233	period
O	2234	2237	had
O	2238	2240	an
O	2241	2250	increased
B-outcome	2251	2257	breast
I-outcome	2258	2264	cancer
I-outcome	2265	2269	risk
O	2270	2271	(
O	2271	2273	HR
O	2273	2274	,
O	2275	2276	1
O	2276	2277	.
O	2277	2279	36
O	2279	2280	;
O	2281	2283	95
O	2283	2284	%
O	2285	2287	CI
O	2287	2288	,
O	2289	2290	1
O	2290	2291	.
O	2291	2292	1
O	2292	2293	-
O	2293	2294	1
O	2294	2295	.
O	2295	2297	65
O	2297	2298	)
O	2298	2299	,
O	2300	2303	but
O	2304	2309	among
O	2310	2315	women
O	2316	2323	already
O	2324	2334	overweight
O	2335	2337	or
O	2338	2343	obese
O	2344	2346	we
O	2347	2352	found
O	2353	2355	no
O	2356	2367	association
O	2368	2370	of
O	2371	2377	weight
O	2378	2384	change
O	2385	2386	(
O	2386	2390	gain
O	2391	2393	or
O	2394	2398	loss
O	2398	2399	)
O	2400	2404	with
O	2405	2411	breast
O	2412	2418	cancer
O	2419	2425	during
O	2426	2432	follow
O	2432	2433	-
O	2433	2435	up
O	2435	2436	.

O	2437	2442	There
O	2443	2446	was
O	2447	2449	no
O	2450	2456	effect
O	2457	2469	modification
O	2470	2472	of
O	2473	2476	the
O	2477	2480	BMI
O	2480	2481	-
O	2481	2487	breast
O	2488	2494	cancer
O	2495	2507	relationship
O	2508	2510	by
O	2511	2525	postmenopausal
O	2526	2533	hormone
O	2534	2541	therapy
O	2541	2542	,
O	2543	2546	and
O	2547	2550	the
O	2551	2560	direction
O	2561	2563	of
O	2564	2575	association
O	2576	2582	across
O	2583	2586	BMI
O	2587	2597	categories
O	2598	2601	was
O	2602	2609	similar
O	2610	2613	for
O	2614	2619	never
O	2619	2620	,
O	2621	2625	past
O	2625	2626	,
O	2627	2630	and
O	2631	2638	current
O	2639	2646	hormone
O	2647	2654	therapy
O	2655	2658	use
O	2658	2659	.

O	2660	2667	Obesity
O	2668	2670	is
O	2671	2681	associated
O	2682	2686	with
O	2687	2696	increased
O	2697	2705	invasive
O	2706	2712	breast
O	2713	2719	cancer
O	2720	2724	risk
O	2725	2727	in
O	2728	2742	postmenopausal
O	2743	2748	women
O	2748	2749	.

O	2750	2755	These
O	2756	2766	clinically
O	2767	2777	meaningful
O	2778	2786	findings
O	2787	2793	should
O	2794	2802	motivate
O	2803	2811	programs
O	2812	2815	for
O	2816	2823	obesity
O	2824	2834	prevention
O	2834	2835	.
O	2836	2850	clinicaltrials
O	2850	2851	.
O	2851	2854	gov
O	2855	2865	Identifier
O	2865	2866	:
O	2867	2878	NCT00000611
O	2878	2879	.
